XNASZVSA
Market cap3mUSD
Jan 17, Last price
1.42USD
1D
5.19%
1Q
-38.26%
IPO
-99.95%
Name
Zyversa Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-98m
L-87.05%
CFO
-9m
L+483.47%
Profile
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | 14,421 | 13,023 | ||
Unusual Expense (Income) | ||||
NOPBT | (14,421) | (13,023) | ||
NOPBT Margin | ||||
Operating Taxes | (9,456) | 745,050 | ||
Tax Rate | ||||
NOPAT | (4,965) | (758,073) | ||
Net income | (98,298) -87.05% | (759,098) 8,423.89% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 7,411 | 1,865 | ||
BB yield | -844.58% | -1.31% | ||
| Debt | ||||
Debt current | 9 | 109 | ||
Long-term debt | 9 | 109 | ||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | (3,120) | (5,685) | ||
| Cash flow | ||||
Cash from operating activities | (8,721) | (1,495) | ||
CAPEX | (1) | |||
Cash from investing activities | ||||
Cash from financing activities | 5,956 | |||
FCF | 17 | (759,873) | ||
| Balance | ||||
Cash | 3,138 | 5,902 | ||
Long term investments | ||||
Excess cash | 3,138 | 5,902 | ||
Stockholders' equity | (103,219) | (4,920) | ||
Invested Capital | 114,302 | 104,917 | ||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 98 | 259 | ||
Price | 9.00 -98.36% | 549.50 | ||
Market cap | 878 -99.38% | 142,586 | ||
EV | (2,243) | 136,901 | ||
EBITDA | (14,410) | (13,014) | ||
EV/EBITDA | 0.16 | |||
Interest | 457 | 428 | ||
Interest/NOPBT | ||||